5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis

dc.contributor.authorMeevassana J.
dc.contributor.authorVarophas S.
dc.contributor.authorPrabsattru P.
dc.contributor.authorKamolratanakul S.
dc.contributor.authorRuangritchankul K.
dc.contributor.authorKitkumthorn N.
dc.contributor.correspondenceMeevassana J.
dc.contributor.otherMahidol University
dc.date.accessioned2024-04-04T18:32:39Z
dc.date.available2024-04-04T18:32:39Z
dc.date.issued2024-12-01
dc.description.abstractThere is a correlation between DNA methylation and the diseased stage and poor survival. 5-methylcytosine (5-mC) is one of the epigenetic modifications of bases that researchers focus on. Staining with 5-mC immunohistochemistry was used to examine pathological samples taken from individuals diagnosed with cutaneous melanoma. Between Breslow levels 2 and 4, there was a significant difference in the H-score of 5-mC expression (p = 0.046). A significant reduction in 5-mC expression H-scores was seen in patients who were diagnosed with ulcers (p = 0.039). It was shown that patients with low 5-mC had a significantly worse overall survival rate (p = 0.027).
dc.identifier.citationScientific Reports Vol.14 No.1 (2024)
dc.identifier.doi10.1038/s41598-024-58011-z
dc.identifier.eissn20452322
dc.identifier.scopus2-s2.0-85188945064
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/97868
dc.rights.holderSCOPUS
dc.subjectMultidisciplinary
dc.title5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85188945064&origin=inward
oaire.citation.issue1
oaire.citation.titleScientific Reports
oaire.citation.volume14
oairecerif.author.affiliationFaculty of Tropical Medicine, Mahidol University
oairecerif.author.affiliationMahidol University, Faculty of Dentistry
oairecerif.author.affiliationFaculty of Medicine, Chulalongkorn University

Files

Collections